0000950170-23-024600.txt : 20230526
0000950170-23-024600.hdr.sgml : 20230526
20230526191049
ACCESSION NUMBER: 0000950170-23-024600
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230524
FILED AS OF DATE: 20230526
DATE AS OF CHANGE: 20230526
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MORTIMER IAN
CENTRAL INDEX KEY: 0001619961
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36687
FILM NUMBER: 23971019
MAIL ADDRESS:
STREET 1: C/O XENON PHARMACEUTICALS INC.
STREET 2: 200 - 3650 GILMORE WAY
CITY: BURNABY
STATE: A1
ZIP: V5G4W8
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Xenon Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0001582313
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 980661854
STATE OF INCORPORATION: A1
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 - 3650 GILMORE WAY
CITY: BURNABY
STATE: A1
ZIP: V5G 48W
BUSINESS PHONE: (604) 484-3300
MAIL ADDRESS:
STREET 1: 200 - 3650 GILMORE WAY
CITY: BURNABY
STATE: A1
ZIP: V5G 48W
4
1
ownership.xml
4
X0407
4
2023-05-24
0001582313
Xenon Pharmaceuticals Inc.
XENE
0001619961
MORTIMER IAN
200 - 3650 GILMORE WAY
BURNABY
Z4
V5G 4W8
CANADA (FEDERAL LEVEL)
true
true
false
false
PRESIDENT & CEO
false
Common Shares
2023-05-24
4
M
false
42592
9.44
A
48592
D
Common Shares
2023-05-24
4
F
false
7310
41.84
D
41282
D
Common Shares
2023-05-24
4
S
false
17069
41.44
D
24213
D
Common Shares
2023-05-24
4
M
false
20576
9.85
A
44789
D
Common Shares
2023-05-24
4
F
false
3902
41.84
D
40887
D
Common Shares
2023-05-24
4
S
false
13179
41.37
D
27708
D
Common Shares
2023-05-24
4
M
false
6172
9.85
A
33880
D
Common Shares
2023-05-24
4
F
false
1171
41.84
D
32709
D
Common Shares
2023-05-24
4
S
false
1407
41.49
D
31302
D
Common Shares
14300
I
By Spouse.
Stock Option (Right to Buy)
9.44
2023-05-24
4
M
false
42592
0
D
2023-07-31
Common Shares
42592
0
D
Stock Option (Right to Buy)
9.85
2023-05-24
4
M
false
20576
0
D
2024-01-13
Common Shares
20576
0
D
Stock Option (Right to Buy)
9.85
2023-05-24
4
M
false
6172
0
D
2024-01-13
Common Shares
6172
0
D
The exercise price was converted from $9.76 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the "Reverse Stock Split"). The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
Represents the closing price of the Company's common shares on May 23, 2023 for purposes of net settlement calculations.
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.29 to $41.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the Reverse Stock
Split. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.26 to $41.47, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.48 to $41.52, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
The shares subject to the option are fully vested and exercisable.
/s/ Cassandra Robinson, Attorney-in-fact
2023-05-26